carbostyril has been researched along with Viremia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, SF; Chang, SY; Chuang, YC; Hsiao, CY; Hsieh, TW; Hsu, JY; Huang, YS; Hung, CC; Liu, WC; Su, YC; Sun, HY | 1 |
| Blondel, L; Charpentier, C; Descamps, D; Joly, V; Landman, R; Lê, M; Matheron, S; Perrier, M; Peytavin, G; Pinto, A; Visseaux, B; Yazdanpanah, Y | 1 |
1 trial(s) available for carbostyril and Viremia
| Article | Year |
|---|---|
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cobicistat; Cohort Studies; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Middle Aged; Polymerase Chain Reaction; Quinolones; RNA, Viral; Tablets; Tenofovir; Viral Load; Viremia | 2017 |
1 other study(ies) available for carbostyril and Viremia
| Article | Year |
|---|---|
Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Incidence; Quinolones; Raltegravir Potassium; Retrospective Studies; Viremia | 2022 |